Drent M L, Zelissen P M, Koppeschaar H P, Nieuwenhuyzen Kruseman A C, Lutterman J A, van der Veen E A
Department of Endocrinology, Free University Hospital, Amsterdam, The Netherlands.
Int J Obes Relat Metab Disord. 1995 May;19(5):299-304.
To investigate the effect of the serotonin receptor agonist dexfenfluramine on eating habits and weight loss in ambulatory, android type, moderately obese patients with an overconsumption of snacks.
9 week, randomized, double-blind treatment with either dexfenfluramine (30 mg/day) or placebo, without dietary intervention.
Outpatient clinics of four University Hospitals in The Netherlands.
112 healthy obese subjects, body mass index 28-35 kg/m2, waist-to-hip ratio > or = 1.0 for men and > or = 0.8 for women, consuming more than five snacks containing in total more than 500 kcal/day and/or more than 25% of total calorie intake in the form of snacks.
Changes in macronutrient composition of the diet, food intake (total, at principal meals and in between meals in the form of snacks) and weight loss.
104 subjects were included for efficacy analysis. In both the dexfenfluramine group (n = 51) and the placebo group (n = 53) the total energy intake decreased. The decrease during main meals was significantly greater in the dexfenfluramine group for all parameters tested except for simple carbohydrates. In between meals the decrease in intake was significantly greater in the dexfenfluramine group for total energy intake (P < 0.05) and intake in unsaturated fat (P < 0.05). The reported reduction in total food intake in the dexfenfluramine group was similarly due to reductions in carbohydrate and fat intake. No weight loss was seen in the placebo group. The treated group lost 3.1 +/- 0.2 kg (P < 0.01).
Dexfenfluramine effectively reduces the intake of carbohydrates as well as fat in ambulatory, non diet restricted android obese subjects by reducing food intake during and in between main meals.
研究血清素受体激动剂右芬氟拉明对非卧床、苹果型、中度肥胖且零食摄入过多患者饮食习惯及体重减轻的影响。
采用右芬氟拉明（30毫克/天）或安慰剂进行为期9周的随机双盲治疗，不进行饮食干预。
荷兰四家大学医院的门诊诊所。
112名健康肥胖受试者，体重指数为28 - 35千克/平方米，男性腰臀比≥1.0，女性腰臀比≥0.8，每天食用超过五份零食，零食总热量超过500千卡和/或零食热量占总热量摄入的25%以上。
饮食中常量营养素组成的变化、食物摄入量（总量、主餐时及以零食形式的餐间摄入量）和体重减轻情况。
104名受试者纳入疗效分析。右芬氟拉明组（n = 51）和安慰剂组（n = 53）的总能量摄入量均下降。除简单碳水化合物外，右芬氟拉明组主餐期间所有测试参数的下降幅度均显著更大。餐间，右芬氟拉明组总能量摄入量（P < 0.05）和不饱和脂肪摄入量（P < 0.05）的下降幅度显著更大。右芬氟拉明组报告的总食物摄入量减少同样归因于碳水化合物和脂肪摄入量的减少。安慰剂组未见体重减轻。治疗组体重减轻3.1±0.2千克（P < 0.01）。
右芬氟拉明通过减少主餐期间及餐间的食物摄入量，有效降低了非卧床、非饮食限制的苹果型肥胖受试者的碳水化合物及脂肪摄入量。
